Adjunctive mealtime use of the amylin analog pramlintide improves postprandial hyperglycemia in patients with type 1 diabetes. This post hoc analysis of three randomized trials evaluated whether disease duration affected responses to pramlintide.
Patients received mealtime pramlintide 30 or 60 µg (n = 714) or placebo (n = 537) as an… (More)
Effects of six months administration of pramlintide as an adjunct to insulin therapy on metabolic control in people with type 1 diabetes. Diabetes. 1999;48(Suppl 1):A113–4 (Abstr 0489)
M Fineman, A Bahner, A Gottleib, O. Kolterman
the diabetes control and complications trial/ epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983–2005)
Diabetes Control Complications Trial Research GroupEpidemiology of Diabetes Interventions, Complications Research Group, Nathan DM, Zinman B. Modern-day clinical course of type 1 diabetes mellitus after 30 years’ duration
Arch Intern Med. 2009;169:1307–16. Adv Ther
In an open - label clinical study pramlintide lowered A 1 c , body weight , and insulin use in patients with type 1 diabetes failing to achieve glycemic targets with insulin therapy